Swimming Upstream in Severe AsthmaNew Pathways to Patient Management
This Industry Program is open to all registered attendees of the American Thoracic Society's 2021 International Conference (ATS 2021).
This activity is provided by Integritas Communications.
This activity is supported by an independent educational grant from AstraZeneca.
Instructions to Participate
There is no registration fee for attending this program. However, you must be a registered attendee of ATS 2021 to participate. Once the ATS 2021 participant portal is open, please find this Industry Program and add it to your conference calendar/agenda.
The educational design of this activity addresses the needs of pulmonologists, clinical immunologists, and other specialist clinicians who treat patients with severe asthma.
This virtual live Interactive Exchange™ severe asthma program will provide a blended educational format that promotes opportunities for various interactions and dialogue among presenting faculty and participants. The program will begin with expert presentations that impart foundational information─including key upstream inflammatory pathways, the role of the epithelium in asthma development, mechanisms underlying characteristic phenotypes, and the rationale for targeted biologic therapies─for the interactive discussions that will follow. Faculty will focus on key topics, such as recent clinical trial evidence for emerging pharmacotherapies that target type 2 (T2)-low disease, evolving evidence-based treatment algorithms, and potential strategies for effectively managing patients with uncontrolled, severe disease. This multimedia experience will deliver optimized participant engagement while ensuring the sharing of experiences surrounding challenging clinical topics in today’s severe asthma landscape.
Upon completion of this activity, participants will be better able to do the following:
- Describe clinically relevant pathophysiologic processes in severe asthma, including implications for new targeted treatment options
- Comprehensively assess patients with asthma for disease severity, lung function, and treatment responses
- Discuss the mechanisms of action and clinical profiles of new and emerging targeted therapies for severe asthma
- Individualized treatment regimens for patients with severe asthma based on symptoms, phenotypes, and patient preferences